Effects of tamsulosin on hypogastric nerve stimulation-induced intraurethral pressure elevation in male and female dogs under anesthesia

被引:10
作者
Ohtake, A [1 ]
Sato, S [1 ]
Saitoh, C [1 ]
Yuyama, H [1 ]
Sasamata, M [1 ]
Miyata, K [1 ]
机构
[1] Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Pharmacol Labs, Tsukuba, Ibaraki 3058585, Japan
关键词
tamsulosin; intraurethral pressure; arterial blood pressure;
D O I
10.1016/j.ejphar.2004.06.066
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the present study was to investigate the effects of tamsulosin, an alpha(1)-adrenoceptor antagonist, on hypogastric nerve stimulation-induced intraurethral pressure elevation in anesthetized male and female dogs and to evaluate sex differences in these effects. Additionally, the effects of tamsulosin were also compared with those of other alpha(1)-adrenoceptor antagonists, namely prazosin, naftopidil and urapidil. Tamsulosin dose-dependently inhibited hypogastric nerve stimulation-induced intraurethral pressure elevation, with doses required to induce 50% inhibition of the elevation (ED50 values) of 0.72 and 0.74 mug/kg i.v. in anesthetized male and female dogs, respectively. Mean arterial blood pressure slightly decreased after administration of tamsulosin at a dose which inhibited intraurethral pressure elevation almost completely. Prazosin, naftopidil and urapidil also inhibited increases in intraurethral pressure in a dose-dependent fashion, but caused decreases in mean arterial blood pressure at the same doses. The estimated rank order of inhibitory potency for urethral response was tamsulosin>prazosin>naftopidil=urapidil. In conclusion, tamsulosin dose-dependently inhibited increases in intraurethral pressure with little effect on mean arterial blood pressure in both male and female dogs, and these effects were almost equipotent. These results indicate that tamsulosin will be useful in the treatment of dysuria associated with lower urinary tract symptoms in women as well as men. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:327 / 334
页数:8
相关论文
共 39 条
[1]   A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha(1A)-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia) [J].
Abrams, P ;
Speakman, M ;
Stott, M ;
Arkell, D ;
Pocock, R .
BRITISH JOURNAL OF UROLOGY, 1997, 80 (04) :587-596
[2]   NEW WORDS FOR OLD - LOWER URINARY-TRACT SYMPTOMS FOR PROSTATISM [J].
ABRAMS, P .
BRITISH MEDICAL JOURNAL, 1994, 308 (6934) :929-930
[3]   5-HT1A-AGONISTIC PROPERTIES OF NAFTOPIDIL, A NOVEL ANTIHYPERTENSIVE DRUG [J].
BORBE, HO ;
METZENAUER, P ;
SZELENYI, I .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 205 (01) :105-107
[4]   SPECIFICITY OF THE AMERICAN-UROLOGICAL-ASSOCIATION VOIDING SYMPTOM INDEX - COMPARISON OF UNSELECTED AND SELECTED SAMPLES OF BOTH SEXES [J].
CHAI, TC ;
BELVILLE, WD ;
MCGUIRE, EJ ;
NYQUIST, L .
JOURNAL OF UROLOGY, 1993, 150 (05) :1710-1713
[5]   Lower urinary tract symptoms/benign prostatic hyperplasia: Fast control of the patient's quality of life [J].
Djavan, B .
UROLOGY, 2003, 62 (3A) :6-14
[6]  
Elliott TR, 1907, J PHYSIOL-LONDON, V33, P367
[7]   USE OF RECOMBINANT ALPHA(1)-ADRENOCEPTORS TO CHARACTERIZE SUBTYPE SELECTIVITY OF DRUGS FOR THE TREATMENT OF PROSTATIC HYPERTROPHY [J].
FOGLAR, R ;
SHIBATA, K ;
HORIE, K ;
HIRASAWA, A ;
TSUJIMOTO, G .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 288 (02) :201-207
[8]  
FORRAY C, 1994, MOL PHARMACOL, V45, P703
[9]   Preclinical pharmacology of fiduxosin, a novel α1-adrenoceptor antagonist with uroselective properties [J].
Hancock, AA ;
Buckner, SA ;
Brune, ME ;
Esbenshade, TA ;
Ireland, LM ;
Katwala, S ;
Milicic, I ;
Meyer, MD ;
Kerwin, JF ;
Williams, M .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (02) :478-486
[10]  
Hatanaka Toshiki, 2001, Journal of Urology, V165, P211